Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tenaya Therapeutics, Inc.

NASDAQ: TNYA · Life Sciences · 2 alerts · CIK 1858848

Share price
$0.3336Close, Nov 16
Market cap
$76M
Shares outstanding
227.93MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tenaya Therapeutics, Inc. filings on SEC EDGAR ↗

4:24 PM ET 10-Q
Financial Results

Tenaya Therapeutics Q3 2026 Results: Net Loss of $18.9M, Loss Narrows

Tenaya Therapeutics reported a significant decrease in total assets from $146.9 million at the end of 2025 to $76.7 million as of September 30, 2026, driven by a reduction in cash and property assets. The company's accumulated deficit increased to $686.6 million, reflecting ongoing research and development losses as it advances its gene therapy pipeline for heart disease.

Key figure
Net loss $18.9M
4:14 PM ET 8-K
Financial Results

Tenaya Therapeutics Financial Results

Tenaya Therapeutics reported third quarter 2026 financial results, ending the period with $66.8 million in cash which provides a runway into Q4 2027. The company highlighted the recent FDA RMAT designation for its TN-401 gene therapy and expects to provide clinical data updates and pivotal trial planning feedback for both TN-201 and TN-401 by year-end.

“As we celebrate the tenth anniversary of Tenaya, we are entering one of the most important periods in the Company’s history. The forthcoming data updates from TN-201 and TN-401, together with regulatory feedback on potential pivotal development pathways, are expected to inform potential opportunities to advance these programs toward late-stage development.”

Faraz Ali, Chief Executive Officer of Tenaya

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.